GLP-1RAs belong to the incretin-based therapies with subcutaneous or oral administration that are currently approved for the treatment of T2DM and obesity (Table 1) [24,25]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.